Background Although the benefit of thrombolytic therapy in reducing mortality in acute
myocardial infarction is well established, the types of bleeding and risk factors for bleeding …

Background There is conclusive evidence from clinical trials that thrombolytic therapy
reduces mortality in acute myocardial infarction (AMI). But still only a minority of patients …

Background: The comparative clinical effectiveness of new (reteplase, tenecteplase) vs.
older (alteplase, streptokinase) thrombolytic agents in the treatment of acute myocardial …

Background The relative efficacy of streptokinase and tissue plasminogen activator and the
roles of intravenous as compared with subcutaneous heparin as adjunctive therapy in acute …

Background. Many trials in patients with acute myocardial infarction have demonstrated that
thrombolytic therapy is not associated with an excessive risk of stroke, as compared with …

Timely administration of thrombolytic therapy decreases myocardial infarct size, lessens the
incidence of congestive heart failure and improves survival. However, available data …

Objectives. The purpose of this study was to examine the incidence and clinical implications
of thrombocytopenia that occurs in hospital after administration of thrombolytic therapy for …

This chapter about antithrombotic therapy for acute myocardial infarction (MI) is part of the
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …

In the past 10 years, thrombolytics have become standard therapy for acute myocardial
infarction. Although the ability of streptokinase to lyse clot was first recognised in the 1930s …

Background—Nonhemorrhagic stroke occurs in 0.1% to 1.3% of patients with acute
myocardial infarction who are treated with thrombolysis, with substantial associated mortality …